The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center has announced the winners of their 7th annual Paper of the Year Award.
We are pleased to share that their choice for best cost-effectiveness analysis published in 2024 was Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States, coauthored by Anita Brogan, Ashley Davis, and colleagues.
These researchers assessed the lifetime cost-effectiveness of cabotegravir long-acting (CAB-LA), an injectable drug for pre-exposure prophylaxis (PrEP) against HIV, compared with generic oral PrEP in the United States. Their paper was chosen from a competitive pool of nominations for its novelty, implementation of real-world data, and exemplary use of health equity considerations in economic evaluations.
Click here to read the research.
Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-461. doi: 10.1007/s40273-023-01342-y.